Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, Thomson EC, da Silva Filipe A, Aranday-Cortes E, Ansari MA, Brown A, Hudson E, Benselin J, Healy B, Troke P, McLauchlan J, Barnes E, Irving WL. Smith DA, et al. Among authors: irving wl. J Viral Hepat. 2021 Sep;28(9):1256-1264. doi: 10.1111/jvh.13549. Epub 2021 Jun 8. J Viral Hepat. 2021. PMID: 34003556 Free article.
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. Bucci C, et al. J Gen Virol. 2013 Jun;94(Pt 6):1259-1265. doi: 10.1099/vir.0.051052-0. Epub 2013 Mar 13. J Gen Virol. 2013. PMID: 23486666
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ, Ito T, Irving WL. Backx M, et al. Among authors: irving wl. J Viral Hepat. 2014 Mar;21(3):208-15. doi: 10.1111/jvh.12132. Epub 2013 Aug 1. J Viral Hepat. 2014. PMID: 24438682
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. Martin NK, et al. J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7. J Viral Hepat. 2015. PMID: 25288193 Free PMC article.
230 results